Search Results

Cortexyme, Inc. today provided a business update and announced key milestones for 2022.

Cortexyme, Inc. today announced that it entered into an agreement under which the company plans to acquire Novosteo, a privately-held biotech company focused on targeted therapeutics to treat rare skeletal diseases, bone cancer and injury.

Cortexyme, Inc. announced changes to its leadership team, including appointing Christopher Lowe as interim chief executive officer.

Cortexyme, Inc. (Nasdaq: CRTX), a clinical-stage biopharmaceutical company developing therapeutic approaches to improve the lives of patients diagnosed with degenerative diseases, today announced the completion of its acquisition of Novosteo, a privately-held biotech company focused on targeted therapeutics to treat rare skeletal diseases, bone cancer and injury.

Cortexyme Corporate Name Change to Quince Therapeutics to Take Effect on August 1, 2022.

Cortexyme, Inc. today announced that its board of directors has appointed Christopher Lowe, the company’s chief operating officer and chief financial officer, as interim chief executive.

Cortexyme, Inc. (Nasdaq: CRTX), a clinical-stage biopharmaceutical company focused on rare and degenerative diseases, today announced the appointment of June Bray, a pharmaceutical industry veteran and global drug development and regulatory process expert, to the company’s Board of Directors.

Cortexyme Announces Clinical Hold on Atuzaginstat’s Investigational New Drug Application.

Cortexyme, Inc. today announced the appointment of Marwan Noel Sabbagh, MD, FAAN, a board-certified neurologist and leading expert in Alzheimer’s and dementia care, to the company’s Board of Directors.